4 December 2023

Media Contact

Taylor Marks

Manager, Marketing & Communications

Society of Interventional Oncology (SIO) Announces First European Site Activated in Groundbreaking ACCLAIM Clinical Trial

Washington, DC (4 December 2023) – The Society of Interventional Oncology (SIO) proudly announces the National and Kapodistrian University of Athens, Greece, as the first European site approved for enrollment and activated for the society’s primary clinical trial, “Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure.” Under SIO President-elect Professor Alexis Kelekis, MD, PhD, EBIR, FSIR, FCIRSE, Associate Professor Dimitrios Filippiadis, MD, PhD, MSc, EBIR, FCIRSE, will act as the principal site investigator. The 2nd Department of Radiology of the National and Kapodistrian University of Athens is the sixth site approved and activated for the ACCLAIM trial.

Dr. Constantinos T. Sofocleous is the Global Principal Investigator for the study. “We are excited and pleased to share the opening of our first European site approved to enroll in the ACCLAIM Trial and sixth site overall for the project,” said Sofocleous. “We look forward to announcing our other sites as they are approved for enrollment to begin in Europe.” 

Participants of the ACCLAIM Trial will be patients with a diagnosis of colorectal cancer liver metastases. MWA will be performed using an CE Marked or FDA-cleared, commercially available MWA system, and using margin confirmation (visualization) software. Upon its launch, the ACCLAIM study is expected to have a three-year enrollment period of 275 participants across sites in the United States and Europe.

This multimillion-dollar trial is funded collectively through grants from Boston Scientific CorporationNeuWave Medical, Inc. (part of Ethicon, Inc.), and Varian, a Siemens Healthineers Company.


About the Society of Interventional Oncology (SIO) 

SIO serves as the only membership-based organization dedicated to the emerging field of interventional oncology (IO), working to establish, nurture, and support IO as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. IO therapies, such as embolization and tumor ablation, combine the expertise of oncology and radiology and use imaging technology to diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. For more information, please visit

About the ACCLAIM (Ablation with Confirmation of Colorectal Liver Metastases) Trial

In this multi-center, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins. The study is the first global, prospective trial to use an objective and reproducible technical outcome in its study design, which SIO believes will drive important changes to future treatment guidelines. The study will incorporate software to assess the ablation zone and margins and determine if achieving complete margins during an ablation equates to procedural success, where the primary outcome is local disease progression at two-years post-ablation. For more information, please visit,

Twitter  Linkedin  Facebook